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Edited by Sandro SonninoAbstract Fibril formation of islet amyloid polypeptide (IAPP) is
associated with cell death of the insulin-producing pancreatic b-
cells in patients with Type 2 Diabetes Mellitus. A likely cause for
the cytotoxicity of human IAPP is that it destroys the barrier
properties of the cell membrane. Here, we show by ﬂuorescence
confocal microscopy on lipid vesicles that the process of hIAPP
amyloid formation is accompanied by a loss of barrier function,
whereby lipids are extracted from the membrane and taken up in
the forming amyloid deposits. No membrane interaction was
observed when preformed ﬁbrils were used. It is proposed that lipid
uptake from the cell membrane is responsible for amyloid-induced
membrane damage and that this represents a general mechanism
underlying the cytotoxicity of amyloid forming proteins.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Amyloid ﬁbril proteins are associated with a number of
seemingly unrelated diseases. Examples are the (human) islet
amyloid polypeptide (hIAPP) in type 2 diabetes mellitus and
the neuronal Ab in Alzheimer’s disease. During the patho-
genesis of these diseases, amyloid formation is associated with
death of insulin-producing pancreatic islet b-cells [1] and of
neuronal cells [2], respectively. Amyloidogenic proteins share
the ability to form oligomeric and ﬁbrillar aggregates with a
common structure [3,4]. Since the cytotoxic mode of action of
the various amyloid-forming proteins seems to be similar, in-
dependent of whether their aggregates are formed inside or
outside of the cell, it was recently suggested that these protein* Corresponding author. Present address: Physical Chemistry 1, Center
for Chemistry and Chemical Engineering, Lund University, P.O. Box
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the cell membrane [3]. Indeed, there is increasing evidence that
amyloid-forming proteins can interact strongly with mem-
branes [5–12]. However, it is not clear what the precise con-
sequences are of these interactions for the membrane, or how
they are related to ﬁbril formation. Yet the process of ﬁbril
formation is critical for cytotoxicity: small oligomeric aggre-
gates that form early in the aggregation process appear to be
the most detrimental to cells, while mature ﬁbrils do not show
any cytotoxicity [3,12,13].
Recent studies on hIAPP have shown that binding of this
protein to model membranes increases the rate of ﬁbril for-
mation and it was proposed that the membrane surface acts as
catalyst for this process [8]. Other studies have shown that
hIAPP can induce aspeciﬁc membrane leakage in a variety of
model membranes [9,10,14]. Here, we studied simultaneously
the process of hIAPP-induced membrane leakage and amyloid-
ﬁber formation in the presence of lipid membranes. For this, we
used model systems of giant unilamellar lipid vesicles (GUVs)
and living rat insulinoma tumor (RIN) cells, to which mono-
meric IAPP was added. The aggregation process was investi-
gated by means of laser confocal ﬂuorescence microscopy. This
assay allows us to simultaneously monitor the localization of
lipids and peptides, alterations in the membrane structure and
vesicle leakage by using diﬀerent ﬂuorescent dyes. We show
that during amyloid formation, the membrane barrier becomes
disrupted and that this process is accompanied by extraction of
lipids from the membrane. These lipids are taken up in the
forming amyloid aggregates. We propose that it is the extrac-
tion of the lipids from the cell membrane that is responsible for
the membrane leakage and, based on our own results combined
with recent literature data, we suggest that this represents a
general mechanism that leads to amyloid-induced cell death.2. Materials and methods
2.1. Materials
1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-
sn-glycero-3-phospho-L-serine (DOPS) were obtained from Avantiblished by Elsevier B.V. All rights reserved.
Fig. 1. hIAPP–membrane interactions. Confocal ﬂuorescence images
showing equatorial sections of GUVs before (A) and after (B–F) the
addition of monomeric hIAPP; B: 1 min, C: 2–3 min, D: 4–5 min, E: 5–
6 min and F: ca 10 min. The GUVs are composed of DOPC and
rhodamine-PE (red) (0.05% of the total amount of lipids). The aqueous
phase contains carboxyﬂuorescein (green), which is added after the
preparation of the GUVs. Membrane disruption, leakage and protein–
lipid aggregate formation is observed after the addition of hIAPP.
Images (A–E) superimpose the green and the red channels, and image
(F) superimposes the red channel and the simultaneously obtained
Nomarski optical microscopy image. Scale bars: 25 lm.
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from Molecular Probes (the Netherlands). C-terminally amidated hu-
man and mouse IAPP1-37 were custom synthesized and HPLC-puri-
ﬁed (>98%) (from Bachem (Switzerland) and Dutch Cancer Institute
(the Netherlands)). Ab(1–40) was synthesized and puriﬁed by Dr.
D.T.S. Rijkers (Faculty of Pharmacy, Utrecht University).
2.2. Vesicle preparation
GUVs were prepared by electroformation [15,16] in a ﬂow chamber
with Pt electrodes. Lipids in chloroform/methanol (9/1) (5 mM) were
deposited at the Pt electrodes and the solvent was evaporated at 50 C.
After adding 300 ll of 50 mM HEPES buﬀer at pH 7.0 into the
chamber, a voltage of 4 V at 10 Hz was applied for at least 1 h.
GUVs were prepared of DOPC and of mixtures of DOPC with 30
molar% DOPS, and the lipid ﬂuorescent probes were added at a
concentration of 0.05% of the total amount of lipids.
2.3. Rat insulinoma tumor (RIN) cells
The RIN cells were cultured in RPMI 1640 (Gibco) containing 10%
fetal calf serum, 11 mM glucose, 300 mg/l L-glutamine, 2000 mg/l
NaHCO3, 100 IU/ml penicillin and 100 lg/ml streptomycin in a hu-
midiﬁed incubator with 5% CO2 at 37 C. The cells were incubated
with the membrane lipid probes in the serum-free medium for 20 min
and excess dye was washed away prior to the addition of the protein.
The experiments were performed in PBS buﬀer, pH 7.2, supplemented
with 0.9 mM CaCl2, 0.5 mM MgCl2 and 5 mM glucose.
2.4. Fluorescence labeling
The GUVs and the RIN cells were labeled with diﬀerent membrane
probes; the headgroup labeled Rhodamine-PE (N-(6-tetramethyl-
rhodaminethiocarbamoyl)-1,2-di-palmitoyl-sn-glycero-3-phosphoetha-
nolamine) and the acyl chains labeled NBD-PC (1-palmitoyl-2-[6-[(7-
nitro-2,1,3-benzoxadiazol-4-yl)amino]caproyl]-sn-glycero-3-phospho-
choline), b-Bodipy (581/591)-PC (1-palmitoyl-2-(4,4-diﬂuoro-5-(4-
phenyl-1,3-butadienyl)-4-bora-3a,4a-diaza-s-indacene-3-pentanoyl)-
sn-glycero-3-phosphocholine) and b-Bodipy (FL)-PC (1-palmitoyl-
2-(4,4-diﬂuoro-5,7-dimethyl-4-bora-3a, 4a-diaza-s-indacene-3-penta-
noyl)-sn-glycero-3- phosphocholine).
2.5. Confocal ﬂuorescence microscopy
Images were taken with a Nikon Eclipse TE2000-U inverted mi-
croscope, equipped with C1 confocal laser scanning unit and CFI Plan
Fluor 40· objective, N.A 1,30. The green and red ﬂuorescence signals
were acquired using double excitation (488 nm line from an Argon–Ion
laser and 543 nm line from a He–Ne laser) and detection (emission
bandpass ﬁlters 515/30 and 585/30). The GUVs and the RIN cells were
inspected by microscopy before the addition of the protein. The pro-
teins were added from a freshly prepared DMSO stock solution to a
ﬁnal protein concentration of 3–5 lM.3. Results and discussion
Confocal ﬂuorescence microscopy allows monitoring of the
eﬀects of amyloid forming proteins on membrane integrity and
morphology by using a combination of water-soluble ﬂuores-
cent dyes and lipid-speciﬁc probes, which are incorporated in
the membrane. In addition, it allows monitoring the formation
of amyloid ﬁbers by using an amyloid ﬁber-speciﬁc reagent.
Therefore, with this technique it is possible to analyze several
processes involving hIAPP–membrane interactions in one
sample. As illustrated in Fig. 1A, the membrane of giant un-
ilamellar vesicles (GUVs) of DOPC can be visualized by in-
cluding the ﬂuorescent lipid dye rhodamine-PE (red) in the
membrane. Simultaneously, the intactness of the barrier
function is demonstrated by the inability of the water-soluble
dye carboxyﬂuorescein (green), added on the outside, to pen-
etrate the vesicles. The addition of monomeric hIAPP to
GUVs results in a loss of barrier function, as shown by the
appearance of the green water-soluble dye inside the vesicles
(Fig. 1B). It also results in the appearance of small irregularaggregates containing ﬂuorescent lipids on the outside of the
vesicles (Fig. 1B). In time, the irregular aggregates grow in size
on the outside of the vesicles (Fig. 1C–E) and, ﬁnally, the
vesicles collapse (Fig. 1F). In the ﬁnal state of the experiment,
no intact vesicles are observed in the vicinity of the formed
aggregates. The visibility of the formed aggregates by No-
marski optics (Fig. 1F) indicates that they contain protein
aggregates. However, the aggregates must also include sub-
stantial amounts of lipids as implied from the presence of the
ﬂuorescent lipids and from the observation that the membrane
lipids from the GUVs are consumed by the aggregates during
the association process.
That lipids are taken up in the forming hIAPP aggregates is
further conﬁrmed by the co-localization of the amyloid-speciﬁc
dye Congo-Red (red) with lipid-speciﬁc probes (green) at
various stages of the process (Fig. 2A and B). Formation of
lipid-containing amyloid aggregates is also observed when
hIAPP is added to intact living cells, where the cell membrane
is visualized after incubation with a ﬂuorescent lipid dye
(green). Fig. 2C and D show that the addition of monomeric
hIAPP to rat insulinoma tumor (RIN) cells leads to extraction
of lipids from the cell membrane and co-localization of pro-
tein- and lipid-speciﬁc probes in the ﬁbrillar aggregates. The
presence of ﬂuorescent lipid in the aggregates was observed
Fig. 3. Schematic representation of the proposed mechanism for the
formation of amyloid protein–lipid aggregates in the presence of lipid
Fig. 2. Co-localization of hIAPP and membrane lipids. Confocal
ﬂuorescence images showing the equatorial sections of GUVs 4–5 min
after the addition of monomeric hIAPP (A,B) and an amyloid aggre-
gate at the surface of rat insulinoma tumor (RIN) cells (C,D). The
GUVs are composed of DOPC and NBD-PC (green) (0.05% of the
total amount of lipids). The cells were incubated with Bodipy(FL)-PC
(green). In both cases, hIAPP amyloid aggregates are localized by
staining with the amyloid-speciﬁc dye Congo Red (red). The images
show co-localization of the amyloid protein (B,D) and lipids (A,C).
Scale bars: 25 lm.
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in the headgroups or in the acyl chains (e.g., Rhodamin-PE,
NBD-PC, Bodipy(581/591)-PC and Bodipy(FL)-PC).
We also observed that hIAPP amyloid formation is sensitive
to the lipid composition. Incorporation of anionic lipids, such as
phosphatidylserine, in the zwitterionic phosphatidylcholine
vesicles resulted in signiﬁcant acceleration of both the formation
of the protein–lipid aggregates and the loss of barrier function
(not shown). This is consistent with the recent literature data,
which show that hIAPP interacts more strongly with mem-
branes containing anionic lipids [8] and suggests that electro-
static interactions between the positively charged proteins and
the negatively charged membrane surface enhance the protein–
membrane interactions that are responsible for membrane
damage and formation of lipid-containing hIAPP aggregates.
The uptake of membrane lipids into the amyloid is directly
coupled to the process of amyloid formation, as is inferred
from the following observations. First, none of the eﬀects de-
scribed above, i.e., membrane leakage, changes in membrane
morphology, or formation of lipid-containing amyloid aggre-
gates, is observed to a signiﬁcant extent when preformed
hIAPP ﬁbrils are added to the membranes (not shown). Sec-
ond, the structurally related non-amyloidogenic mouse IAPP
(mIAPP) (Table 1), which does not form ﬁbrils [17], causesTable 1
Amino acid sequences for hIAPP (top) and mIAPP (bottom)
hIAPP KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSN-
TY-CONH2
mIAPP KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSN-
TY-CONH2
The peptides diﬀer in the central region comprising amino acids 20–29.none of these eﬀects when added to GUVs or intact living cells.
Moreover, although mIAPP is more positively charged than
hIAPP, we did not observe an interaction with negatively
charged vesicles under the experimental conditions that we
used. Finally, the formation of lipid-hIAPP amyloid aggre-
gates can be inhibited by addition of mIAPP (not shown),
which can act as a b-sheet blocker [18]. Thus, aggregation of
hIAPP seems directly associated with extraction of lipid from
the membrane to the forming protein–lipid aggregates, and
with the accompanying alterations in membrane structure and
function. This is in line with the recent suggestion that leakage
of vesicles upon interaction with hIAPP is due to lipid loss
from the membrane rather than to the formation of discrete
protein pores [9].
Membrane-disruption and formation of protein–lipid ag-
gregates, albeit at a slower rate, is also observed at the mem-
brane when the amyloidogenic Ab(1–40) is added to GUVs
(not shown). This is consistent with the observations from
Michikawa et al, showing that oligomeric Ab can promote
lipid release from neurons and astrocyte cells [19]. Moreover,
uptake of lipids in forming ﬁbers has been shown to occur for a
variety of water-soluble proteins [20]. Thus, our results suggestmembranes. I: The aggregation process starts when monomeric pro-
teins are added to the aqueous solution. II: Attractive interaction be-
tween the lipid bilayer and the protein oligomers and/or monomers
leads to accumulation of proteins at the lipid bilayer. III: Aggregation
continues at the lipid membrane, whereby lipids are taken up by the
forming aggregates. The extraction of lipids from the membrane also
causes local disruption of the membrane barrier. IV: Aggregation
continues. Large protein–lipid aggregates are formed for which the
membrane may serve as a template. The aggregates include amyloid
proteins as well as lipids from the membrane.
120 E. Sparr et al. / FEBS Letters 577 (2004) 117–120that induction of membrane leakage concomittant with the
formation of lipid-containing amyloid aggregates is a universal
property of amyloid proteins when aggregating in the presence
of either natural membranes in living cells or lipid bilayers in
model systems.
We propose the following mechanism for the cooperative
process of disruption of membrane barrier function and for-
mation of lipid-containing amyloid aggregates (Fig. 3). The
oligomeric and/or monomeric amyloid proteins accumulate at
the membrane due to strong interactions between the lipid
bilayer and the hydrophobic b-sheet-containing amyloid olig-
omers. Accumulation of amyloid proteins at the membrane
then facilitates nucleation and the growth of lipid-containing
amyloid aggregates, resulting in membrane disruption. In ad-
dition, the lipid membrane can serve as a template for protein
aggregation, as suggested by the observation that the hIAPP-
lipid amyloid aggregates formed in the presence of GUVs often
adopt a nearly circular shape with a diameter of typically 15–
40 lm, reﬂecting the shape and size of the template intact
GUVs (Fig. 1F).
In conclusion, we show that aggregating IAPP takes up
lipids when added to lipid membranes, and that the extraction
of lipids is directly coupled to the process of amyloid forma-
tion and to the permeabilization of the lipid membrane. The
fact that we observe similar eﬀects for hIAPP and Ab indicates
a general phenomenon that is independent of the way that the
amyloid aggregates are formed in nature, lending further
support to the recent hypothesis that the membrane is the
common target for these proteins [3].Acknowledgements: E.S. has received ﬁnancial support from The
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